Atlas Trials

Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease

Clinical trial NCT00528073 · COMPLETED

Trial details

NCT number
NCT00528073
Sponsor
Alfasigma S.p.A.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Crohn's Disease
Start date
2007-09-01
Primary completion
2009-03-01
Enrollment
410

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.